The JAK Inhibitors Drug Development Summit is the only industry-dedicated platform for large pharma, innovative biotech and KOLs of academia to harness the full therapeutic opportunity of JAK inhibitors in the clinic.
Focusing on optimized selectivity, drug-drug interactions, safety and efficacy challenges to successfully translate and develop the next generation of superior JAK inhibitors join the leaders in this space as you strengthen your pipelines and leverage expertise to design and create the right clinical strategy.
With numerous clinical candidates demonstrating genuine viability in targeting the JAK/STAT pathway, join the experts in JAK inhibitor development to participate in cross-disciplinary discussions that are transforming JAK Inhibitor strategies into the best and first in class approaches for patients in need.
“The content was fantastic. The speakers were wonderful as well. It was a great educational forum and it is nice to see experts in academia, government, and industry working towards one goal of bringing safe and innovative products for patients.”
Jennifer Lee, Senior Medical Science Liaison, Sanofi Genzyme
"With so many webinar/virtual event providers in the market right now, it can be difficult to find the ones of value - Hanson Wade have stepped above the rest by providing actionable sales connections with our target market."
Vijendra NALAMOTHU PhD, Chairman & CEO, Tergus Pharma
Meet Our World-Class Speaker Faculty
Chief Executive Officer
Chief Scientific Officer
Chief, Translational Immunology Section
National Institute of Arthritis & Musculoskeletal & Skin Diseases
Associate Professor & Founder/Chief Scientific Officer
Washington University School of Medicine & Nuogen Pharma